PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-09-12

Date Title Company
12-Sep-2022 Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Businesswire
12-Sep-2022 Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint Businesswire
12-Sep-2022 Meaghan Hafner Appointed to Vice President, Health Care Businesswire
12-Sep-2022 Establishment Labs Announces Hani Zeini has Joined the Company as Exclusive Advisor in Anticipation of US Launch Businesswire
12-Sep-2022 Fierce Biotech Names Synthekine as One of Its “Fierce 15” Biotech Companies of 2022 Businesswire
12-Sep-2022 Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer Businesswire
12-Sep-2022 Bluestar Genomics Presents Data on New Applications of its Epigenomic Cancer Detection Platform Businesswire
12-Sep-2022 Introducing Wellful Inc.: Nutrisystem and Adaptive Health Announce New Parent Company Name Businesswire
12-Sep-2022 Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022 Businesswire
12-Sep-2022 Global White Oil Market Analysis Report 2022-2028: Extensive Industrialization in Emerging Economies & Elevating Demand as Adhesive in Food Packaging - ResearchAndMarkets.com Businesswire
12-Sep-2022 Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer Businesswire
12-Sep-2022 Hygieia adds clinical partners in New York and North Carolina to its d-Nav® Insulin Management Program Businesswire
12-Sep-2022 L’étude de phase III évaluant trifluridine/tipiracil en association au bevacizumab chez des patients ayant un cancer colorectal métastatique réfractaire a atteint son objectif principal d’amélioration de survie globale Businesswire
12-Sep-2022 Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer Businesswire
12-Sep-2022 Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology Businesswire
12-Sep-2022 Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology Businesswire
12-Sep-2022 Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd
12-Sep-2022 Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022 Fierce Biotech
12-Sep-2022 NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor’s Eczema Balm on Return QVC® Appearance Businesswire
12-Sep-2022 TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers Businesswire